Search the Newsreel

Mereo BioPharma Group (NASDAQ:MREO) Issues Quarterly Earnings Results

Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights

Mereo BioPharma Group plc Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo's investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) Mereo and partner Ultragenyx engaging with regulatory agencies on potential path forward for setrusumab in osteogenesis imperfecta (OI); …

Mereo BioPharma Group plc Q2 2026: Revenue $0 Net loss $7.01M, EPS $(0.01) — 10-Q Summary

Mereo BioPharma Group plc (MREO) reported financial results for Q2 2026, showing $0 revenue and a net loss of $7.005 million, or $(0.01) per diluted share, which is an improvement compared to the $14.616 million net loss in Q2 2025. The company's business highlights …

Mereo BioPharma licenses alvelestat to Sentynl Therapeutics

Mereo BioPharma has entered into an option and license agreement with Sentynl Therapeutics for alvelestat, an oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease. Under the agreement, Mereo could receive a non-refundable option fee, $40 million in upfront and R&D payments upon option exercise, …

Mereo BioPharma Group PLC (MREO) Stock News Today

This article provides current stock information for Mereo BioPharma Group PLC (MREO), including its stock price, market cap, and a note that more news is coming soon. The page serves as a hub for news, analysis, financials, and other investment-related data for the company.

Mereo BioPharma Group (MREO) Expected to Post Quarterly Earnings on Tuesday

MREO|Mereo BioPharma Group PLC|Price:0.318|Chg%:+0.012

This article provides a comprehensive stock analysis of Mereo BioPharma Group PLC (MREO), highlighting its strong fundamentals and high growth potential, despite recent weak stock market performance. The company, which specializes in therapeutics for rare diseases, is considered fairly valued and has high institutional …

Mereo BioPharma Group PLC (MREO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Mereo BioPharma Group PLC (MREO), detailing its current price momentum score, support and resistance levels, and the readings from various technical indicators and moving averages. According to the analysis, the stock's price momentum score is 4.13, and …

Mereo BioPharma Group PLC (MREO) Cash Flow

This article provides a detailed cash flow statement for Mereo BioPharma Group PLC (MREO), including quarterly data for operating, investing, and financing activities. It breaks down various cash flow components and explains their significance through a series of FAQs. The report indicates financial figures …

Mereo BioPharma Group Market Sentiment

This article provides an overview of market sentiment for Mereo BioPharma Group (MREO), including an "Outperform" analyst consensus from 8 analysts with an average price target of $5.00. It highlights a bullish options flow with a 0.00 P/C ratio and 560 calls versus 2 …

Mereo BioPharma Group plc Revenue Breakdown – NASDAQ:MREO

Mereo BioPharma Group plc reported a total revenue of $500,000 USD last year, with its Rare Disease Therapies segment accounting for the entirety of this amount. This represents a significant decrease compared to the previous year's revenue of $10,000,000 USD from the same segment. …

MREO|Mereo BioPharma Group PLC|Price:0.290|Chg%:-0.001

Mereo BioPharma Group PLC (MREO) is a biopharmaceutical company focused on developing therapeutics for rare diseases, with a high growth potential and relatively healthy fundamentals. Despite an average stock market performance, analysts rate the stock as "Buy" with a significant upside potential, though it …

Mereo BioPharma Group PLC (MREO) Institutional Confidence

Mereo BioPharma Group PLC (MREO) has an institutional shareholding score of 3.00, placing it 192nd out of 386 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 43.84%, a 38.82% decrease quarter-over-quarter. James Simons is the largest institutional shareholder, holding 48.59K …

Mereo BioPharma Group PLC (MREO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Mereo BioPharma Group PLC (MREO) has an earnings forecast score of 8.00, ranking 168th in the Biotechnology & Medical Research industry. The average price target from 8 analysts is $7.00, with a strong buy consensus. The company's expected revenue for the next quarter is …

Mereo BioPharma Group PLC (MREO) Risk Assessment: Volatility, Financial Risk & Investment Risk

Mereo BioPharma Group PLC (MREO) Valuation: PE, PB & Fair Value Analysis

This article analyzes the valuation of Mereo BioPharma Group PLC (MREO), indicating its current valuation score of 6.99, ranking 276 out of 386 in its industry. The company's P/E ratio is noted as -1.31, significantly below its recent high, though other crucial valuation metrics …